Niagen Bioscience, Inc. (NASDAQ:NAGE) announced Monday it has increased its full-year 2025 net sales growth forecast to between 25% and 30% year-over-year, up from its previous projection of 22% to 27%. The company has demonstrated strong execution, with revenue growing 35.9% over the last twelve months and maintaining healthy gross margins of 63.6%.
The company, which specializes in NAD+ (nicotinamide adenine dinucleotide) science and healthy aging research, cited recent regulatory developments as potentially beneficial to its business outlook. According to the company, the FDA’s reversal of previous rulings on the DSHEA drug preclusion rule relating to NMN (nicotinamide mononucleotide) could increase awareness of the NAD+ precursor market.
Niagen Bioscience’s core product is Niagen, a patented nicotinamide riboside (NR) supplement designed to boost NAD+ levels. The company manufactures its products in the United States.
"Elevating NAD+ is critical for health, especially as we age, and greater attention to this important area of science is valuable for public health and for Niagen Bioscience," said Rob Fried, CEO of Niagen Bioscience, in the press release.
The company also noted that its market surveillance program has tested various NAD+ supplements on the market and claims that NMN supplements currently available infringe upon existing patent portfolios related to NMN crystallization.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.